Our finding of a suggestive association between the CYP19A1 gene variant and stomach cancer contrasts with observational studies which have shown that menopausal hormone therapy is associated with a lower risk of stomach cancer (30, 31). This evidence concerns the gene CYP19A1 and gastric neoplasm.